Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Krausch

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Medizinische Klinik (Munich, Germany : 1983)|January 7, 1998
[Effect of selenium administration on various laboratory parameters of patients at risk for sepsis syndrome]C Lehmann, K Egerer, M Weber, et al.
Der Anaesthesist|March 3, 2004
[The effect of dopexamine and iloprost on plasma disappearance rate of indocyanine green in patients in septic shock]J Birnbaum, C Lehmann, K Taymoorian, et al.
Nature Medicine|June 1, 1997
Monocyte deactivation in septic patients: restoration by IFN-gamma treatmentW D Döcke, F Randow, U Syrbe, et al.
Intensive Care Medicine|October 1, 1996
Monocyte deactivation--rationale for a new therapeutic strategy in sepsisH D Volk, P Reinke, D Krausch, et al.
Zeitschrift Fur Ernahrungswissenschaft|April 29, 1998
Parenteral selenium supplementation in critically ill patients--effects on antioxidant metabolismC Lehmann, M Weber, D Krausch, et al.
Archives of Internal Medicine|February 24, 1997
Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principleW J Kox, R C Bone, D Krausch, et al.
Clinical Drug Investigation|May 23, 2007
Efficacy and Safety of the Platelet-Activating Factor Receptor Antagonist BN 52021 (Ginkgolide B) in Patients with Severe Sepsis : A Randomised, Double-Blind, Placebo-Controlled, Multicentre TrialD M Albrecht, K van Ackern, H-J Bender, et al.
Critical Care Medicine|May 1, 1996
Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging studyK Reinhart, C Wiegand-Löhnert, F Grimminger, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Medizinische Klinik (Munich, Germany : 1983)|January 7, 1998
[Effect of selenium administration on various laboratory parameters of patients at risk for sepsis syndrome]C Lehmann, K Egerer, M Weber, et al.
Der Anaesthesist|March 3, 2004
[The effect of dopexamine and iloprost on plasma disappearance rate of indocyanine green in patients in septic shock]J Birnbaum, C Lehmann, K Taymoorian, et al.
Nature Medicine|June 1, 1997
Monocyte deactivation in septic patients: restoration by IFN-gamma treatmentW D Döcke, F Randow, U Syrbe, et al.
Intensive Care Medicine|October 1, 1996
Monocyte deactivation--rationale for a new therapeutic strategy in sepsisH D Volk, P Reinke, D Krausch, et al.
Zeitschrift Fur Ernahrungswissenschaft|April 29, 1998
Parenteral selenium supplementation in critically ill patients--effects on antioxidant metabolismC Lehmann, M Weber, D Krausch, et al.
Archives of Internal Medicine|February 24, 1997
Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principleW J Kox, R C Bone, D Krausch, et al.
Clinical Drug Investigation|May 23, 2007
Efficacy and Safety of the Platelet-Activating Factor Receptor Antagonist BN 52021 (Ginkgolide B) in Patients with Severe Sepsis : A Randomised, Double-Blind, Placebo-Controlled, Multicentre TrialD M Albrecht, K van Ackern, H-J Bender, et al.
Critical Care Medicine|May 1, 1996
Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging studyK Reinhart, C Wiegand-Löhnert, F Grimminger, et al.
Pageof 2